Clinical Trials
2 trialsNCT03207347 2023-09-15
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
University of Florida
Phase 2 Completed
NCT03925350 2021-10-22
Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
California Pacific Medical Center Research Institute
Phase 2 Unknown